01
Latest News/ Blog
Biomarker and ctDNA Testing: A Personalized Approach to Cancer Care
Cancer diagnosis often brings many questions: Which treatment is most suitable for me? Is my treatment working? Has cancer changed? Could it come back? Every person’s cancer is different. Even
Gene Solutions Study Finds Preterm-Birth Signals in Routine triSure NIPT Data
A Gene Solutions study published in American Journal of Obstetrics & Gynecology (AJOG) Global Reports finds cell-free DNA fragmentomic patterns associated with spontaneous preterm birth, pointing to a potential path toward
Gene Solutions Study in AJOG Global Reports Shows Routine NIPT Data May Help Predict First-Trimester Preterm Birth Risk
Preterm birth (PTB), defined as delivery before 37 completed weeks of gestation, remains one of the most consequential and difficult-to-predict complications in obstetric care. It affects roughly 11% of live
ESMO Congress 2026: Gene Solutions to Present AI-Enabled Multi-omic Liquid Biopsy
Gene Solutions will host an Industry Satellite Symposium at ESMO Congress 2026, bringing together international experts to examine how AI-enabled multi-omics and cell-free DNA analysis can move from technological innovation
Gene Solutions Malaysia Advances Conversations on Earlier Cancer Detection at NCCM 2026
Bridging gaps, building hope, and empowering lives. Gene Solutions Malaysia was proud to partner with the National Cancer Society Malaysia (NCSM) at the National Cancer Congress Malaysia (NCCM) 2026,
Gene Solutions Hosts Symposium on ctDNA-Guided Breast Cancer Management at the Thai Breast Disease Society Annual Conference 2026
Clinical perspectives and Asian real-world evidence highlight the role of multi-omic profiling and hybrid ctDNA monitoring in precision breast cancer care. Bangkok, Thailand – 19 August 2026 – Gene Solutions Thailand hosted a dedicated symposium at the Thai Breast Disease Society
SPOT-MAS CRC: Expanding Colorectal Cancer Screening Through Blood-Based Methylation Testing
Article Summary: SPOT-MAS CRC is a non-invasive test using blood-based SEPTIN9 gene methylation detection to support screening of early-stage colorectal cancer and advanced precancerous lesions. Achieving a sensitivity of 77.34%
Advancing Earlier Detection of Gynecologic Cancers Through DNA Methylation
Vietnam’s National Hospital of Obstetrics and Gynecology and Gene Solutions jointly organized a scientific symposium to discuss how DNA methylation biomarkers may support earlier detection and more precise risk stratification
Beyond Imaging: Multi-omics and AI Advance Lung Cancer Screening at Vietnam Respiratory Society Congress 2026
Regional respiratory experts explored how circulating tumor DNA, AI, and multi-omics could complement LDCT, refine pulmonary-nodule risk assessment, and support earlier cancer detection. Under the theme “Cooperation for Lung Health,” the Annual Congress of
Advances in Gynaecological Cancer Management
On 9 July 2026 in Kuala Lumpur, Gene Solutions Malaysia hosted its educational symposium, “Advances in Gynaecological Cancer Management,” building on the scientific discussions presented by Gene Solutions at the 30th International
Gene Solutions Advances Precision Oncology Education in Malaysia with the ”Beyond Actionable” Academy
At the Precision Oncology Academy 2026, leading international experts explored how insights from tumour DNA and RNA can reveal treatment opportunities, explain drug resistance, and translate into more confident treatment decisions to
Bringing multi-cancer early detection closer to everyday family medicine
At the Taiwan Association of Family Medicine Annual Meeting 2026, Gene Solutions Taiwan joined family medicine physicians, laboratory professionals, and clinical researchers to discuss the evolving role of multi-cancer early
02
Press release
Gene Solutions Study Finds Preterm-Birth Signals in Routine triSure NIPT Data
Key finding:
A Gene Solutions study published in American Journal of Obstetrics & Gynecology (AJOG) Global Reports finds cell-free DNA fragmentomic patterns associated with spontaneous preterm birth, pointing to a potential path toward earlier pregnancy-risk assessment. SINGAPORE, Sept. 25, 2026 /PRNewswire/ — Gene Solutions, a global biotechnology company providing precision cell-free DNA solutions through multi-omics and artificial intelligence to improve pregnancy care, cancer detection and precision medicine, today announced the publication of a study showing the potential to assess the risk of spontaneous preterm birth from cell-free DNA fragmentomic signals already present in routine first-trimester non-invasive prenatal testing (NIPT) data.Authors:
GENE SOLUTIONS SGP PTE. LTD.Gene Solutions Advances Precision Oncology Education in Malaysia with the ”Beyond Actionable” Academy
Key finding:
KUALA LUMPUR, Malaysia, Aug. 4, 2026 /PRNewswire/ — Gene Solutions Malaysia hosted the Precision Oncology Academy 2026 on 25 July 2026 at the Sheraton Petaling Jaya Hotel under the theme ”Beyond Actionable”. An extension of the international K-CONNECT Platform and the recent K-CONNECT Summit 2026 in Vietnam, the Academy brought together oncology experts from the United Arab Emirates, Singapore, Malaysia, US and Vietnam. Through scientific lectures, multidisciplinary case discussions and interactive workshops, the programme addressed a central question: How can a deeper understanding of each patient’s cancer lead to more informed treatment decisions?Authors:
GENE SOLUTIONS SGP PTE. LTD.
Gene Solutions Showcases Global Evidence and Responsible Innovation in Prenatal and Women’s Genomic Health at ISPD 2026
Key finding:
SINGAPORE, July 22, 2026 /PRNewswire/ — Gene Solutions, a global biotechnology company focused on accessible and responsible genomics, participated as a Premier Partner at the 30th International Conference on Prenatal Diagnosis and Therapy (ISPD 2026), held virtually from July 7–9. Across an industry symposium, a scientific session, two oral presentations and three scientific posters, the company presented data and expert perspectives on how genomics, epigenomics and artificial intelligence may support more comprehensive, personalized and minimally invasive care throughout pregnancy and across women’s health.Authors:
GENE SOLUTIONS SGP PTE. LTD.
Gene Solutions’ SPOT-MAS 10 Places Asia-Led Cancer Screening Innovation in the Global Spotlight
Key finding:
A blood-based cancer screening technology developed in Asia is gaining international attention after real-world data from more than 84,145 individuals were presented at ASCO Breakthrough 2026 and highlighted by the American Society of Clinical Oncology. For Gene Solutions, this milestone underscores the growing global relevance of Asia-led multi-cancer detection innovation.Authors:
GENE SOLUTIONS SGP PTE. LTD.
Gene Solutions Hosts K-CONNECT Summit 2026, Uniting Oncology Experts Across Asia-Pacific
Key finding:
DA NANG, Vietnam, June 18, 2026 /PRNewswire/ — Gene Solutions announced the successful conclusion of K-CONNECT Summit 2026, a regional scientific forum that brought together leading oncology experts, clinicians, researchers and healthcare stakeholders to discuss how Artificial Intelligence (AI) and multi-omics are reshaping cancer care across Asia-Pacific.Authors:
GENE SOLUTIONS SGP PTE. LTD.
FDA Breakthrough Device Designation Marks Major Milestone for Gene Solutions’ SPOT-MAS 10 Multi-Cancer Screening Test
Key finding:
SINGAPORE, May 27, 2026 /PRNewswire/ — Gene Solutions, a global biotechnology company advancing accessible genomic solutions for cancer detection and precision oncology, today announced that the U.S. Food and Drug Administration has granted Breakthrough Device Designation to SPOT-MAS 10, its multi-omic blood test designed to detect cancer-associated signals.Authors:
GENE SOLUTIONS SGP PTE. LTD.
Gene Solutions Showcases AI-Powered Multi-Omics Liquid Biopsy Innovations at TJCC 2026: Advancing Precision Oncology in Taiwan
Key finding:
TAIPEI, May 22, 2026 /PRNewswire/ — Gene Solutions, an innovative global biotechnology company advancing AI-powered multi-omics solutions for cancer detection and precision oncology, participated in the 30th Taiwan Joint Cancer Conference (TJCC 2026), marking its first major oncology conference presence in Taiwan.Authors:
Gene Solutions Genomics Pte Ltd
Gene Solutions Announces Strategic Entry into Türkiye with Robust Real-World Evidence at the 2nd International Hereditary Cancers Congress 2026
Authors:
Gene Solutions Genomics Pte Ltd
triSure NIPT Debuts in Taiwan, Expanding Non-Invasive Prenatal Screening Beyond Aneuploidy
Key finding:
TAIPEI, April 14, 2026 /PRNewswire/ — At the prestigious Taiwan Association of Obstetrics and Gynecology (TAOG) 2026 Annual Meeting—the nation’s largest obstetrics and gynecology society established in 1961— Gene Solutions Taiwan officially introduced triSure, a revolutionary non-invasive prenatal screening technology.Authors:
Gene Solutions Genomics Pte Ltd
World Cancer Day: Genomics & AI Blood Test Detects Cancer Before Symptoms Appear in India
Gene Solutions and Pangea Laboratory Establish Strategic Collaboration to Validate Laboratory Developed ctDNA Tests for Precision Screening and Cancer Care in the U.S.
Key finding:
IRVINE, Calif., Jan. 21, 2026 /PRNewswire/ — Gene Solutions, a global biotechnology company, and Pangea Laboratory, a CLIA-certified, CAP-accredited Next Generation Sequencing (NGS) leader in validation platforms for Laboratory Developed Tests (LDTs), announced a strategic collaboration to advance U.S. verification and clinical validation of liquid biopsy assays designed for cancer detection, profiling, and monitoring.Authors:
Gene Solutions Genomics Pte Ltd
Gene Solutions Concludes Successful ESMO Asia Congress 2025 with AI-Powered Multi-Omics Liquid Biopsy Symposium and Two Best Poster Awards
Key finding:
SINGAPORE, Dec. 20, 2025 /PRNewswire/ — Gene Solutions, a pioneering genetic testing company, announced key achievements at the European Society for Medical Oncology (ESMO) Asia Congress 2025—held in Singapore on December 5–7. Highlights included a full-house symposium, seven scientific abstracts with two earning Best Poster designations, and meaningful engagement with thousands of oncologists from across the Asia-Pacific region at the company’s exhibition booth.Authors:
Gene Solutions Genomics Pte Ltd
